Top

Published in:

01-01-2010

Neurotoxicity of Cancer Treatment

Author: Marc C. Chamberlain

Published in: Current Oncology Reports | Issue 1/2010

Abstract

Cancer therapy—including brain-directed surgery, brain or spine irradiation, or chemotherapy—may affect the nervous system in a deleterious manner, affecting either the central or peripheral nervous systems. The causation of encephalopathy (eg, radiation, chemotherapy) is most relevant for the differential diagnosis of central nervous system (CNS) disorders, as defining a specific cause determines further treatment and outcome. Peripheral nervous system disorders (ie, steroid myopathy, spindle poison, or platinum neuropathy) are predominantly treatment related and respond best to discontinuation of the neurotoxic agent.

Ulmer S, Braga TA, Barker FG, et al.: Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006, 67:1668–1670.CrossRefPubMed

Smith JS, Cha S, Mayo MC, et al.: Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg 2005, 103:428–438.CrossRefPubMed

Khan RB, Gutin PH, Raj SN, et al.: Use of diffusion weighted magnetic resonance imaging in predicting early postoperative outcome of new neurological deficits after brain tumor resection. J Neurosurg 2006, 59:60–65.CrossRef

Chang SM, Parney IF, McDermott M, et al.: Perioperative complications and neurological outcomes for first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 2003, 98:1175–1181.CrossRefPubMed

Litofsky NS, Farace E, Anderson F Jr, et al.: Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004, 54:358–366.CrossRefPubMed

Jackson RJ, Fuller GN, Abi-Said D, et al.: Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001, 3:193–200.CrossRefPubMed

Bernstein M, Parrent AG: Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosorg 1994, 81:165–168.CrossRef

Leibel S, Sheline G: Tolerance of the brain and spinal cord to conventional irradiation. In Radiation Injury to the Nervous System. Edited by Gutin P LS, Sheline G. New York: Raven Press; 1991:239–256.

Tofilon PJ, Fike JR: The radioresponse of the central nervous system: a dynamic process. Radiat Res 2000, 153:357–370.CrossRefPubMed

10.

• Kim JH, Brown SL, Jenrow KA, Ryu S: Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. J Neurooncol 2008, 87:279–286. This article provides an excellent overview of radiation injury of the brain.

11.

Belka C, Budach W, Kortmann RD, Bamberg M: Radiation induced CNS toxicity—molecular and cellular mechanisms. Br J Cancer 2001, 85:1233–1239.CrossRefPubMed

12.

New P: Radiation injury to the nervous system. Curr Opin Neurol 2001, 14:725–734.CrossRefPubMed

13.

de Wit MC, de Bruin HG, Eijkenboom W, et al.: Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004, 63:535–537.PubMed

14.

Chamberlain MC, Glantz MJ, Chalmers L, Sloan A: Early necrosis following temodar and radiotherapy in patients with glioblastoma. J Neuro Oncol 2007, 82:81–83.CrossRef

15.

• Brandsma D, Stalpers L, Taal W, et al.: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453–461. This article offers an excellent overview of pseudoprogression in high-grade gliomas treated with combined chemoradiation.

16.

Brandes AA, Tosoni A, Franceschi E, Sotti G, et al.: Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009, 27:1275–1279.CrossRefPubMed

17.

Yoshii Y: Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 2008, 25:51–58.CrossRefPubMed

18.

Packer RJ, Gurney JG, Punyko JA, et al.: Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 2003, 21:3255–3261.CrossRefPubMed

19.

Kumar AJ, Leeds NE, Fuller GN, et al.: Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000, 217:377–384.PubMed

20.

Leber KA, Eder HG, Kovac H, et al.: Treatment of cerebral radionecrosis by hyperbaric oxygen therapy. Stereotact Funct Neurosurg 1998, 70:229–236.CrossRefPubMed

21.

Glantz MJ, Burger PC, Friedman AH, et al.: Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994, 44:2020–2027.PubMed

22.

• Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67:323–326. This article discusses the first study to demonstrate an effective treatment, bevacizumab, for radiation-induced cerebral necrosis.

23.

Weitzner MA, Meyers CA, Bryne K: Psychosocial functioning and quality of life in patients with primary tumors. J Neurosurg 1996, 84:29–34.CrossRefPubMed

24.

Taphoorn MJB, Stupp R, Coens C, et al.: Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol 2005, 6:937–944.CrossRefPubMed

25.

Meyers CA, Smith JA, Bezjak A, et al.: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157–165.CrossRefPubMed

26.

Aoyama H, Tago M, Katoh N, et al.: Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007, 68:1388–1395.PubMed

27.

•• Li J, Bentzen SM, Renschler M, Mehta M: Regression after whole brain radiation therapy for brain metastases correlates with survival and improved neurocognitive outcome. J Clin Oncol 2007, 25:1260–1266. This article discusses a prospective trial indicating the importance of tumor response to radiation as a predictor of cognition in patients with brain metastases treated with whole brain radiotherapy.

28.

Meyers CA, Brown PD: Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006, 24:1305–1309.CrossRefPubMed

29.

Gregor A, Cull A, Stephens RJ, et al.: Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a Multicenter randomized trial: United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for research and treatment of Cancer (EORTC). Eur J Cancer 1997, 33:1752–1758.CrossRefPubMed

30.

•• Wefel JS, Cloughesy TF, Zazzali J, et al. Neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study [abstract 338]. Neurooncology 2009, 11:641. This article offers a prospective evaluation of neurocognition in patients with recurrent glioblastoma treated with bevacizumab.

31.

Glantz MJ, Chamberlain MC, Liu Q, et al.: Gender disparity in the rate of partner abandonment in patients with serious medical illness. Cancer 2009, 115:5237–5242.CrossRefPubMed

32.

Nimjee SM, Powers CJ, Bulsara KR, et al.: Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. Neurosurg Focus 2009, 21:e4.

33.

Recht L, Mrugala M: Neurologic complications of hematologic neoplasms. Neurol Clin N Am 2003, 21:87–105.

34.

Plotkin SR, Wen PY: Neurologic complications of cancer therapy. Neurol Clin N Am 2003, 21:279–318.

35.

Gilbert MR: The neurotoxicity of chemotherapy. Neurologist 1998, 4:43–53.CrossRef

36.

Pruitt AA: Nervous system infections in patients with cancer. Neurol Clin N Amer 2003, 21:193–219.

37.

Hinchey J, Chaves C, Appignani B, et al.: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494–500.CrossRefPubMed

38.

Herzig RH, Hines, Herzig GP, et al.: Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987, 5:927–932.PubMed

39.

Rosenfeld MS, Pruitt A: Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol 2006, 33:352–361.CrossRefPubMed

40.

•• Vardy J, Wefel JS, Ahles T, et al.: Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008, 19:623–629. This article offers an excellent overview of chemotherapy-related cognitive dysfunction.

41.

Tannock IF, Ahles TA, Ganz PA, van Dam FS: Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004, 22:2233–2239.CrossRefPubMed

42.

Chamberlain MC, Kormanik PA, Barba D: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurgery 1997, 87:694–699.CrossRef

43.

Glantz MJ, Jaeckle KA, Chamberlain MC, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394–3402.PubMed

44.

Loblaw DA, Perry J, Chambers A, Laperriere NJ: Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol 2005, 23:2028–2037.CrossRefPubMed

45.

Dalmau J, Rosenfeld MR: Paraneoplastic neurologic syndromes. In Harrison’s Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, et al. New York: McGraw-Hill; 2005:571–575.

46.

Kori SH, Foley KM, Posner JB: Brachial plexus lesions in patients with cancer: 100 cases. Neurology 1981, 31:45–50.PubMed

47.

Dworkin RH, Johnson RW, Breuer J et al.: Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44:S1–S26.CrossRefPubMed

48.

Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J. Neurol 2002, 249:9–17.CrossRefPubMed

49.

Gregg RW, Molepo JM, Monpetit VJ, et al.: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992, 10:795–803.PubMed

50.

Owczarek J, Jasinska M, Orszulak-Michalak D: Drug-induced myopathies: an overview of the possible mechanisms. Pharmacol Rep 2005, 57:23–34.PubMed

Title: Neurotoxicity of Cancer Treatment
Author: Marc C. Chamberlain
Publication date: 01-01-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 1/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-009-0072-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Modern Multidisciplinary Management of Brain Metastases

Biology and Therapy of Neoplastic Meningitis

The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Neurologic Complications of Cancer and its Treatment

Advances in the Treatment of Malignant Gliomas

The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer